{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:21:46Z","timestamp":1792174906155,"version":"4.4.0"},"reference-count":25,"publisher":"American Society of Hematology","issue":"24","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,12,23]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Patients with therapy-related acute lymphoblastic leukemia (t-ALL) represent a small subset of acute lymphoblastic leukemia (ALL) patients who received genotoxic therapy (ie, chemotherapy or radiation) for a prior malignancy. These patients should be distinguished from patients with de novo ALL (dn-ALL) and ALL patients who have a history of prior malignancy but have not received cytotoxic therapies in the past (acute lymphoblastic leukemia with prior malignancy [pm-ALL]). We report a retrospective multi-institutional study of patients with t-ALL (n = 116), dn-ALL (n = 100), and pm-ALL (n = 20) to investigate the impact of prior cytotoxic therapies on clinical outcomes. Compared with patients with pm-ALL, t-ALL patients had a significantly shorter interval between the first malignancy and ALL diagnosis and a higher frequency of poor-risk cytogenetic features, including KMT2A rearrangements and myelodysplastic syndrome-like abnormalities (eg, monosomal karyotype). We observed a variety of mutations among t-ALL patients, with the majority of patients exhibiting mutations that were more common with myeloid malignancies (eg, DNMT3A, RUNX1, ASXL1), whereas others had ALL-type mutations (eg, CDKN2A, IKZF1). Median overall survival was significantly shorter in the t-ALL cohort compared with patients with dn-ALL or pm-ALL. Patients who were eligible for hematopoietic cell transplantation had improved long-term survival. Collectively, our results support t-ALL as a distinct entity based on its biologic and clinical features.<\/jats:p>","DOI":"10.1182\/bloodadvances.2019000925","type":"journal-article","created":{"date-parts":[[2019,12,23]],"date-time":"2019-12-23T17:25:57Z","timestamp":1577121957000},"page":"4228-4237","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":60,"title":["Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes"],"prefix":"10.1182","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7617-8356","authenticated-orcid":false,"given":"Caner","family":"Saygin","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, The Ohio State University, Columbus, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwin","family":"Kishtagari","sequence":"additional","affiliation":[{"name":"Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3424-2425","authenticated-orcid":false,"given":"Ryan D.","family":"Cassaday","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, University of Washington School of Medicine, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Reizine","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Chicago Comprehensive Cancer Center, Chicago, IL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilana","family":"Yurkiewicz","sequence":"additional","affiliation":[{"name":"Department of Medicine, Stanford University School of Medicine, Stanford, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8945-5850","authenticated-orcid":false,"given":"Michaela","family":"Liedtke","sequence":"additional","affiliation":[{"name":"Department of Medicine, Stanford University School of Medicine, Stanford, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Stock","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Chicago Comprehensive Cancer Center, Chicago, IL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9168-3203","authenticated-orcid":false,"given":"Richard A.","family":"Larson","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Chicago Comprehensive Cancer Center, Chicago, IL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross L.","family":"Levine","sequence":"additional","affiliation":[{"name":"Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin S.","family":"Tallman","sequence":"additional","affiliation":[{"name":"Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae H.","family":"Park","sequence":"additional","affiliation":[{"name":"Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassandra","family":"Kerr","sequence":"additional","affiliation":[{"name":"Translational Hematology\/Oncology, Cleveland Clinic, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bartlomiej","family":"Przychodzen","sequence":"additional","affiliation":[{"name":"Translational Hematology\/Oncology, Cleveland Clinic, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikkael A.","family":"Sekeres","sequence":"additional","affiliation":[{"name":"Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt E.","family":"Kalaycio","sequence":"additional","affiliation":[{"name":"Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5241-3614","authenticated-orcid":false,"given":"Hetty E.","family":"Carraway","sequence":"additional","affiliation":[{"name":"Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betty K.","family":"Hamilton","sequence":"additional","affiliation":[{"name":"Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Sobecks","sequence":"additional","affiliation":[{"name":"Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3422-1309","authenticated-orcid":false,"given":"Aaron","family":"Gerds","sequence":"additional","affiliation":[{"name":"Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudipto","family":"Mukherjee","sequence":"additional","affiliation":[{"name":"Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aziz","family":"Nazha","sequence":"additional","affiliation":[{"name":"Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaroslaw P.","family":"Maciejewski","sequence":"additional","affiliation":[{"name":"Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH;"},{"name":"Translational Hematology\/Oncology, Cleveland Clinic, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0015-5902","authenticated-orcid":false,"given":"Anjali S.","family":"Advani","sequence":"additional","affiliation":[{"name":"Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2019,12,23]]},"reference":[{"issue":"12","key":"2020012414593912400_B1","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia","volume":"373","author":"D\u00f6hner","year":"2015","journal-title":"N Engl J Med"},{"issue":"31","key":"2020012414593912400_B2","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1200\/JCO.2014.60.0890","article-title":"Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a national population-based cohort study","volume":"33","author":"Granfeldt \u00d8stg\u00e5rd","year":"2015","journal-title":"J Clin Oncol"},{"issue":"20","key":"2020012414593912400_B3","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia [published correction appears in Blood 2016;128(3):462-463]","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"16","key":"2020012414593912400_B4","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1002\/cncr.26735","article-title":"Therapy-related acute lymphoblastic leukemia is more frequent than previously recognized and has a poor prognosis","volume":"118","author":"Abdulwahab","year":"2012","journal-title":"Cancer"},{"issue":"1","key":"2020012414593912400_B5","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/bjh.13386","article-title":"Secondary acute lymphoblastic leukaemia is constitutional and probably not related to prior therapy","volume":"170","author":"Ganzel","year":"2015","journal-title":"Br J Haematol"},{"key":"2020012414593912400_B6","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.leukres.2018.07.024","article-title":"Secondary acute lymphoblastic leukemia, a retrospective analysis from Washington University and meta-analysis of published data","volume":"72","author":"Ferraro","year":"2018","journal-title":"Leuk Res"},{"issue":"6","key":"2020012414593912400_B7","doi-asserted-by":"crossref","first-page":"919","DOI":"10.3324\/haematol.2011.057752","article-title":"Precursor B-acute lymphoblastic leukemia occurring in patients with a history of prior malignancies: is it therapy-related?","volume":"97","author":"Tang","year":"2012","journal-title":"Haematologica"},{"issue":"10","key":"2020012414593912400_B8","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.3324\/haematol.2018.193599","article-title":"Therapy-related acute lymphoblastic leukemia has distinct clinical and cytogenetic features compared to de novo acute lymphoblastic leukemia, but outcomes are comparable in transplanted patients","volume":"103","author":"Aldoss","year":"2018","journal-title":"Haematologica"},{"issue":"2","key":"2020012414593912400_B9","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/cam4.1266","article-title":"Second primary acute lymphoblastic leukemia in adults: a SEER analysis of incidence and outcomes","volume":"7","author":"Swaika","year":"2018","journal-title":"Cancer Med"},{"issue":"12","key":"2020012414593912400_B10","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.leukres.2015.09.011","article-title":"Secondary acute lymphoblastic leukemia is an independent predictor of poor prognosis","volume":"39","author":"Giri","year":"2015","journal-title":"Leuk Res"},{"issue":"9","key":"2020012414593912400_B11","doi-asserted-by":"crossref","first-page":"e605","DOI":"10.1038\/bcj.2017.81","article-title":"Secondary acute lymphoblastic leukemia is a distinct clinical entity with prognostic significance","volume":"7","author":"Rosenberg","year":"2017","journal-title":"Blood Cancer J"},{"issue":"5","key":"2020012414593912400_B12","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1038\/bmt.2015.8","article-title":"Therapy-related ALL: cytogenetic features and hematopoietic cell transplantation outcome","volume":"50","author":"Aldoss","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"2020012414593912400_B13","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3109\/10428194.2015.1040013","article-title":"Incidence, clinical and biological characteristics and outcome of secondary acute lymphoblastic leukemia after solid organ or hematologic malignancy","volume":"57","author":"Kelleher","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"2020012414593912400_B14","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.6004\/jnccn.2017.0147","article-title":"NCCN guidelines insights: acute lymphoblastic leukemia, version 1.2017","volume":"15","author":"Brown","year":"2017","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"2020012414593912400_B15","doi-asserted-by":"crossref","first-page":"680","DOI":"10.5858\/2006-130-680-CACFCI","article-title":"9-color and 10-color flow cytometry in the clinical laboratory","volume":"130","author":"Wood","year":"2006","journal-title":"Arch Pathol Lab Med"},{"issue":"2","key":"2020012414593912400_B16","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3324\/haematol.2017.175810","article-title":"Rational management approach to pure red cell aplasia","volume":"103","author":"Balasubramanian","year":"2018","journal-title":"Haematologica"},{"issue":"7","key":"2020012414593912400_B17","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.bbmt.2017.03.017","article-title":"Multicolor flow cytometry and multigene next-generation sequencing are complementary and highly predictive for relapse in acute myeloid leukemia after allogeneic transplantation","volume":"23","author":"Getta","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"18","key":"2020012414593912400_B18","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1200\/JCO.2017.75.0232","article-title":"Risk of hematologic malignancies after radioiodine treatment of well-differentiated thyroid cancer","volume":"36","author":"Molenaar","year":"2018","journal-title":"J Clin Oncol"},{"issue":"7540","key":"2020012414593912400_B19","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/nature13968","article-title":"Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia","volume":"518","author":"Wong","year":"2015","journal-title":"Nature"},{"issue":"1","key":"2020012414593912400_B20","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/s41375-018-0213-y","article-title":"Acute lymphoblastic leukemia as a clonally unrelated second primary malignancy after multiple myeloma","volume":"33","author":"Aldoss","year":"2019","journal-title":"Leukemia"},{"issue":"1","key":"2020012414593912400_B21","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/sj.leu.2403187","article-title":"Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML","volume":"18","author":"Schoch","year":"2004","journal-title":"Leukemia"},{"issue":"1","key":"2020012414593912400_B22","doi-asserted-by":"crossref","first-page":"e85554","DOI":"10.1371\/journal.pone.0085554","article-title":"Survival of adults with acute lymphoblastic leukemia in Germany and the United States","volume":"9","author":"Pulte","year":"2014","journal-title":"PLoS One"},{"issue":"4","key":"2020012414593912400_B23","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1053\/j.seminoncol.2008.04.012","article-title":"Therapy-related myeloid leukemia","volume":"35","author":"Godley","year":"2008","journal-title":"Semin Oncol"},{"issue":"20","key":"2020012414593912400_B24","doi-asserted-by":"crossref","first-page":"11592","DOI":"10.1073\/pnas.191211198","article-title":"Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia [published correction appears in Proc Natl Acad Sci USA. 2001;98(26):15394]","volume":"98","author":"Allan","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"2020012414593912400_B25","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/ajh.23908","article-title":"Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: a report from the Swedish Acute Leukemia Registry","volume":"90","author":"Huleg\u00e5rdh","year":"2015","journal-title":"Am J Hematol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/24\/4228\/1630438\/advancesadv2019000925.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/24\/4228\/1630438\/advancesadv2019000925.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,14]],"date-time":"2021-02-14T00:10:47Z","timestamp":1613261447000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/3\/24\/4228\/429985\/Therapyrelated-acute-lymphoblastic-leukemia-is-a"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,23]]},"references-count":25,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2019,12,23]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2019000925","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,23]]}}}